Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades
Jason P. Cooper(University of Washington), Brenda M. Sandmaier(University of Washington), Judith A. Shizuru(Stanford University), George E. Georges(Northwestern University), Marco Mielcarek(Fred Hutch Cancer Center), Mary E.D. Flowers(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David G. Maloney(Fred Hutch Cancer Center), Wolfgang Bethge(University of Tübingen), Firoozeh Sahebi(City Of Hope National Medical Center), Parameswaran Hari(Medical College of Wisconsin), George B. McDonald(University of Washington), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Julie Asch(LDS Hospital), Jonathan A. Gutman(University of Colorado Denver), Thomas R. Chauncey(City Of Hope National Medical Center), Ann E. Woolfrey(University of Washington), Amelia Langston(CancerCare Manitoba), Paul J. Martin(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Barry E. Storer(City Of Hope National Medical Center), Bart L. Scott(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael Boyer(Chris O’Brien Lifehouse), Richard T. Maziarz(Oregon Health & Science University), Noa Granot(Fred Hutch Cancer Center), William J. Hogan(Mayo Clinic), Kai Hübel(University Hospital Cologne), G. Olesen(Aarhus University), Andrew M. Yeager(University of Arizona), Edward Agura(Baylor University), Boglark Gyurkocza(University of Washington), Georg‐Nikolaus Franke(University Hospital Leipzig), Søren Lykke Petersen(University of Copenhagen), Michael B. Maris(Colorado Blood Cancer Institute), H. Joachim Deeg(Fred Hutch Cancer Center), Rainer Storb(University of Washington), Mohamed L. Sorror(University of Washington Medical Center)
Cited by 39
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k